Nursing(Degree) · First Year · NUR101
Anatomy and Physiology
Anatomy and Physiology is one of the most important foundation courses for nursing students in Zambia. This course helps you understand how the human body is structured and how it functions, from major organs to body systems such as the nervous, cardiovascular, respiratory, and digestive …
Read more
Anatomy and Physiology is one of the most important foundation courses for nursing students in Zambia. This course helps you understand how the human body is structured and how it functions, from major organs to body systems such as the nervous, cardiovascular, respiratory, and digestive systems. A strong grasp of this subject is essential for exams set by nursing schools and regulatory bodies in Zambia. At 25schools, we simplify complex anatomy concepts using exam-focused questions, diagrams, and clear explanations designed for nursing exams. Whether you are preparing for tests, assignments, or final examinations, this course builds the clinical understanding every successful nurse needs. Start studying with 25schools today and gain the confidence to excel in anatomy and physiology exams.
-
Coming soon
Topic 154Coming soon
Mixed Connective Tissue Disease
Mixed connective tissue disease (MCTD) is an overlap syndrome with features of SLE, SSc, and polymyositis/dermatomyositis, associated with high-titre anti-U1-RNP antibodies. For Zambian students, important to recognize because prognosis better than individual diseases, but may evolve. Pathophysiology: anti-U1-RNP antibodies targeting U1 small nuclear ribonucleoprotein (snRNP) involved in mRNA splicing. Pathogenesis unclear—immune complexes, endothelial activation, cytokine dysregulation. Clinical: overlap features—RAYNAUD'S PHENOMENON (90-95%, often severe, digital ulcers, gangrene), PUFFY HANDS (sausage-like fingers, early), sclerodactyly (late), POLYARTHRITIS (60-80%, non-erosive, RA-like), INFLAMMATORY MYOPATHY (50-70%, proximal weakness, elevated CK), LUPUS-LIKE (malar rash, photosensitivity, alopecia, serositis), PULMONARY HYPERTENSION (10-20%, leading cause death), ILD, oesophageal dysmotility, trigeminal neuropathy, glomerulonephritis (less common, milder than SLE). Diagnosis: HIGH-TITRE ANTI-U1-RNP antibodies + clinical features of ≥2 connective tissue diseases. ANA (speckled) positive. Anti-dsDNA, anti-Sm, anti-Scl-70, anti-Ro/La typically negative or low-titre. Management: ARTHRITIS, RASH, SEROSITIS, FATIGUE: hydroxychloroquine, NSAIDs, low-dose corticosteroids. MYOSITIS: corticosteroids, methotrexate, azathioprine. RAYNAUD'S: calcium channel blockers, PDE5 inhibitors (severe). ILD: mycophenolate, cyclophosphamide, nintedanib. PULMONARY HYPERTENSION: PAH-specific therapy (endothelin antagonists, PDE5 inhibitors, prostacyclin analogues). RENAL: corticosteroids, cyclophosphamide, mycophenolate. Prognosis: variable. 10-year survival 80%. Disease evolution: 30% stable, 30-50% evolve to SSc (most common), SLE, or PM/DM. PAH = major cause death. Zambian context: anti-U1-RNP testing limited; MCTD underrecognized. Clinical diagnosis: overlap features + speckled ANA + severe Raynaud's + puffy hands. Manage organ manifestations as per individual diseases. Hydroxychloroquine, corticosteroids, immunosuppressants (methotrexate, azathioprine) accessible. PAH therapies largely unavailable.
-
Coming soon
Topic 155Coming soon
Behçet's Disease
Behçet's disease (BD) is multisystem vasculitis of unknown etiology, characterized by recurrent oral and genital ulcers, uveitis, and skin lesions. Unusual in sub-Saharan Africa, but recognition important due to silk road distribution and emerging cases. Pathophysiology: vasculitis—affects arteries and veins of all sizes, both thrombosis and aneurysms. HLA-B51 strong association. Neutrophil hyperreactivity (pathergy). Clinical: ORAL ULCERS (100%)—recurrent (>3x/year), painful, aphthous, minor/major/herpetiform, precede other manifestations by years. GENITAL ULCERS (60-80%)—painful, scrotal/vulvar, heal with scar. OCULAR (50%)—uveitis (anterior, posterior, panuveitis), retinal vasculitis, hypopyon (pus in anterior chamber—dramatic but rare). Bilateral, recurrent, leading cause morbidity—blindness. SKIN (80%)—papulopustular lesions (acneiform), erythema nodosum-like, pathergy test positive (24-48h, papule/pustule at needle prick). VASCULAR (25-40%)—superficial thrombophlebitis, DVT, vena cava thrombosis, Budd-Chiari, arterial aneurysms (pulmonary, peripheral). ARTHRITIS (50%)—non-erosive, asymmetric oligoarthritis (knee, ankle). CNS (5-10%)—parenchymal (brainstem, corticospinal), cerebral venous sinus thrombosis, aseptic meningitis. GI (10-30%)—ulcers (ileocecal), similar to Crohn's (distinguish: BD ulcers discrete, fewer, no granulomas). Diagnosis: CLINICAL—International Criteria for Behçet's Disease (ICBD): oral ulcers (2), genital ulcers (2), ocular (2), skin (1), vascular (1), CNS (1), pathergy (1). Score ≥4 = BD. No diagnostic lab test. Pathergy test variable sensitivity. HLA-B51 supports. Management: MUCOCUTANEOUS: topical corticosteroids (ulcers), colchicine, apremilast, TNF inhibitors. OCULAR: corticosteroids, azathioprine, cyclosporine, infliximab, interferon-α. SEVERE ORGAN (vascular, CNS): high-dose corticosteroids, cyclophosphamide, TNF inhibitors. ANTICOAGULATION: controversial for venous thrombosis (concomitant immunosuppression recommended; arterial aneurysms—surgery/endovascular + immunosuppression). Prognosis: relapsing-remitting; blindness, CNS, major vessel disease = poor prognosis. Mortality: young males, arterial aneurysm rupture, CNS, Budd-Chiari. Zambian context: rare, consider in recurrent oral/genital ulcers + uveitis. Pathergy test (forearm needle prick—sterile, read 24-48h). Colchicine for mucocutaneous. Corticosteroids, azathioprine for severe disease. TNF inhibitors unavailable.
-
Coming soon
Topic 156Coming soon
Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is inflammatory disorder of older adults, characterized by severe pain and stiffness of shoulder and pelvic girdles, marked acute phase response, and dramatic response to low-dose corticosteroids. For Zambian students, important in elderly population, differential diagnosis of pain/stiffness, mimics RA, fibromyalgia, malignancy. Pathophysiology: unknown, IL-6 driven. Association with HLA-DRB1*04. Synovitis of proximal joints, bursae (subacromial, trochanteric), tenosynovitis. Clinical: AGE >50 years (peak 70-80). BILATERAL, SYMMETRIC pain and morning stiffness (>45 minutes) of SHOULDER GIRDLE (95%, neck, upper arms), PELVIC GIRDLE (70%, hips, thighs). Systemic: fatigue, malaise, low-grade fever, anorexia, weight loss. DISTINGUISH: weakness is NOT primary—weakness due to pain (patient reluctant to move), not true muscle weakness. Physical exam: pain with active motion, limited range; NO weakness, NO atrophy, NO muscle tenderness. GCA ASSOCIATION (15-20%): headache, scalp tenderness, jaw claudication, visual loss, aortic aneurysm. Diagnosis: CLINICAL. No diagnostic test. Elevated ESR (≥40mm/h, often >100), CRP. Normocytic anaemia, thrombocytosis. CK NORMAL (critical—excludes myopathy). AUTOANTIBODIES: RF, ACPA negative (exclude RA). IMAGING: ultrasound—subacromial/subdeltoid bursitis, biceps tenosynovitis, glenohumeral synovitis; MRI/ PET-CT—periarticular inflammation. TEMPORAL ARTERY BIOPSY if GCA suspected. ACR/EULAR classification criteria: age ≥50, bilateral shoulder aching, AM stiffness >45 min, elevated ESR/CRP, hip pain/limited range, absence RF/ACPA, absence other inflammation. Management: CORTICOSTEROIDS—DRAMATIC RESPONSE (24-72 hours) is hallmark. Prednisone 15-25mg/day, rapid clinical improvement. Taper slowly: reduce 2.5mg q2-4 weeks, goal 5-10mg/day at 3-6 months, total duration 1-2 years. Relapse common with rapid taper. Methotrexate: steroid-sparing (relapse, high cumulative dose). IL-6 inhibitors (tocilizumab): effective, steroid-sparing. CALCIUM, VITAMIN D, BISPHOSPHONATES for osteoporosis prophylaxis. GCA: high-dose prednisone (40-60mg/day), do not wait for biopsy. Prognosis: excellent response to steroids; chronic relapsing course 1-2 years, may require prolonged low-dose therapy. Increased aortic aneurysm risk (late). Zambian context: consider in elderly with new-onset shoulder/hip pain/stiffness, high ESR, dramatic steroid response. Exclude RA (RF/ACPA), myopathy (CK), infection (TB), malignancy. Prednisone accessible, inexpensive. Steroid taper monitoring. Educate patients: PMR is treatable, requires prolonged treatment, not curative, relapse with rapid taper.
-
Coming soon
Topic 157Coming soon
Giant Cell Arteritis
Giant cell arteritis (GCA), also known as temporal arteritis, is the most common primary systemic vasculitis in adults over 50 years, representing a medical emergency due to its potential to cause irreversible blindness. This comprehensive topic provides Zambian tertiary nursing and medical students with essential knowledge for recognizing this time-sensitive condition, initiating emergent therapy, and preventing devastating visual loss. The pathophysiology of GCA is a granulomatous vasculitis targeting medium and large arteries, with predilection for the cranial branches of the aorta, particularly the temporal artery. The inflammatory infiltrate is characterized by CD4+ T cells, macrophages that often fuse to form multinucleated giant cells, and intimal hyperplasia leading to luminal stenosis and tissue ischemia. The disease is strongly associated with polymyalgia rheumatica (PMR), with 15-20% of PMR patients developing GCA, and 40-60% of GCA patients having PMR symptoms. Both conditions share genetic susceptibility (HLA-DRB1*04) and IL-6-driven inflammation. The clinical presentation of GCA is highly variable but typically includes NEW-ONSET HEADACHE (70-85%)—severe, persistent, localized to temporal region, scalp tenderness (difficulty combing hair, wearing glasses). JAW CLAUDICATION (50-65%)—pain with chewing, relieved by rest, highly specific for GCA. VISUAL SYMPTOMS (20-30%)—transient monocular visual loss (amaurosis fugax), diplopia, sudden permanent vision loss due to anterior ischaemic optic neuropathy. Once vision loss occurs, it is IRREVERSIBLE in 80% of affected eyes. SYSTEMIC SYMPTOMS: fever, weight loss, malaise, anaemia. VASCULAR COMPLICATIONS: aortic aneurysm (thoracic), aortic dissection, limb claudication. Up to 20% of GCA patients present with occult disease (fever of unknown origin, isolated aortic involvement). Physical examination may reveal tender, nodular, pulseless temporal artery (beading). Fundoscopy: pale, swollen optic disc (ischaemic optic neuropathy). Diagnosis is based on high clinical suspicion combined with laboratory and histological confirmation. ESR is markedly elevated, often >100 mm/h, with parallel CRP elevation. Normocytic anaemia and thrombocytosis are common. TEMPORAL ARTERY BIOPSY is the gold standard, demonstrating granulomatous inflammation, multinucleated giant cells, fragmentation of internal elastic lamina, and intimal hyperplasia. Biopsy should be performed within 1-2 weeks of initiating corticosteroids, but treatment should NEVER be delayed while awaiting biopsy. Skip lesions mandate adequate biopsy length (3-5 cm) and serial sectioning. False-negative rate is 10-40% due to skip lesions or prior steroid therapy. When clinical suspicion is high and biopsy negative, contralateral biopsy or non-invasive imaging may be considered. High-resolution MRI, temporal artery ultrasound (halo sign—hypoechoic wall thickening), PET-CT (FDG uptake in aorta and branches), and CT angiography are increasingly used for diagnosis and assessment of disease extent. Management of GCA is an EMERGENCY. HIGH-DOSE CORTICOSTEROIDS should be initiated IMMEDIATELY upon clinical suspicion, BEFORE biopsy. Prednisone 40-60 mg daily (or 1 mg/kg/day) for 2-4 weeks, then gradual taper over 12-18 months. For patients with acute visual loss, intravenous methylprednisolone (500-1000 mg daily for 3 days) is recommended to optimize recovery of remaining vision. Clinical and laboratory response (ESR, CRP) guides tapering. Relapse during taper occurs in 40-60%, requiring dose increase. Steroid-sparing agents are increasingly utilized to reduce cumulative glucocorticoid toxicity. Tocilizumab (IL-6 receptor inhibitor), in combination with prednisone taper, is FDA-approved for GCA, demonstrating higher sustained remission rates and reduced steroid exposure. Methotrexate (10-25 mg weekly) provides modest steroid-sparing benefit. Aspirin 75-100 mg daily may reduce ischaemic complications (visual loss, stroke) and is recommended unless contraindicated. Long-term complications of GCA include aortic aneurysm (17-30% at 5-10 years), requiring periodic surveillance imaging (chest X-ray, echocardiography, CT/MR angiography). Prognosis: with prompt treatment, symptoms resolve dramatically within 24-72 hours. Risk of visual loss is confined to the pre-treatment period and the first few days of therapy. Permanent vision loss occurs in 15-20% of patients, usually preventable with early recognition and immediate high-dose corticosteroids. Mortality is not increased in treated GCA, but morbidity from disease and long-term corticosteroid toxicity is substantial. For Zambian clinicians, specific challenges include low awareness of GCA among primary care providers, limited access to temporal artery biopsy and advanced vascular imaging, and need for prolonged corticosteroid therapy with attendant toxicity risks in a population with high burden of tuberculosis, HIV, and hypertension. Despite these challenges, GCA can be diagnosed clinically with high probability in patients over 50 years presenting with new-onset headache, jaw claudication, visual symptoms, and markedly elevated acute phase reactants. Immediate high-dose prednisone is life- and vision-saving. Patient education regarding the urgency of symptom recognition, the requirement for prolonged steroid therapy, and monitoring for corticosteroid side effects is essential. This topic equips Zambian healthcare workers with the knowledge and confidence to recognize, treat, and manage this highly treatable cause of preventable blindness in the elderly.
-
Coming soon
Topic 158Coming soon
Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by arterial, venous, or microvascular thrombosis and/or pregnancy morbidity in the persistent presence of antiphospholipid antibodies (aPL). This comprehensive topic provides Zambian tertiary nursing and medical students with essential knowledge for recognizing this major cause of acquired thrombophilia, recurrent pregnancy loss, and stroke in young adults, and for implementing life-long anticoagulation to prevent catastrophic thrombotic events. The pathophysiology of APS is complex and multifactorial. Antiphospholipid antibodies—including lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and anti-β2-glycoprotein I antibodies (anti-β2GPI)—target phospholipid-binding proteins, particularly β2-glycoprotein I, on the surface of endothelial cells, platelets, and trophoblasts. Rather than directly promoting thrombosis, these antibodies activate endothelial cells (upregulating adhesion molecules, tissue factor), activate platelets, inhibit natural anticoagulant pathways (protein C, protein S, antithrombin, annexin A5 anticoagulant shield), and impair fibrinolysis. The net effect is a prothrombotic state affecting both arterial and venous circulations. Complement activation contributes to pregnancy loss. The clinical classification distinguishes PRIMARY APS (isolated APS) from SECONDARY APS (associated with SLE or other autoimmune diseases). Catastrophic APS (CAPS) is a rare, devastating variant (<1%) characterized by rapidly progressive, widespread small-vessel thrombosis leading to multiorgan failure, with 30-50% mortality despite aggressive therapy. Clinical manifestations of APS are diverse and span virtually every organ system. VASCULAR THROMBOSIS: Venous thrombosis is most common—DVT (30-55%), pulmonary embolism, retinal vein, renal vein, inferior vena cava, cerebral venous sinus. Arterial thrombosis—stroke (50-80% of arterial events), TIA, myocardial infarction, peripheral arterial occlusion. Unusual site thromboses (adrenal, hepatic, mesenteric) are characteristic. PREGNANCY MORBIDITY: Recurrent early miscarriage (<10 weeks, three or more consecutive), fetal death (≥10 weeks, one or more unexplained), severe pre-eclampsia, placental insufficiency, preterm delivery. These complications result from placental infarction and thrombosis. NON-THROMBOTIC MANIFESTATIONS: Cardiac (Libman-Sacks endocarditis—sterile vegetations on mitral/aortic valves, valve thickening, regurgitation), Neurologic (chorea, transverse myelitis, cognitive dysfunction, migraine—mechanisms unclear, may be thrombotic or autoimmune), Hematologic (thrombocytopenia 20-40%, haemolytic anaemia), Renal (APS nephropathy—thrombotic microangiopathy, hypertension, proteinuria), Cutaneous (livedo reticularis, skin ulcers, superficial thrombophlebitis). Diagnosis requires at least ONE clinical criterion (vascular thrombosis OR pregnancy morbidity) AND at least ONE laboratory criterion (LA, aCL IgG/IgM moderate-high titre, anti-β2GPI IgG/IgM) present on TWO or more occasions at least 12 weeks apart. Lupus anticoagulant is the strongest predictor of thrombosis and pregnancy loss. Importantly, transient aPL positivity occurs with infection, medications, and in healthy individuals—persistence is essential for diagnosis. Catastrophic APS (CAPS) is diagnosed by four criteria: involvement of ≥3 organ systems over ≤1 week, histopathological evidence of small vessel thrombosis, laboratory confirmation of aPL, and exclusion of other thrombotic microangiopathies. Differential diagnosis includes hereditary thrombophilias (Factor V Leiden, prothrombin mutation, protein C/S/antithrombin deficiency), other acquired thrombophilias, and heparin-induced thrombocytopenia. Management of APS is stratified by clinical presentation and risk profile. For patients with APS AND thrombotic events: INDEFINITE ANTICOAGULATION is mandatory. Vitamin K antagonists (warfarin) with target INR 2.0-3.0 are standard for venous thrombosis. For arterial thrombosis or recurrent thrombosis despite INR 2-3, higher intensity warfarin (INR 3-4) OR warfarin (INR 2-3) plus low-dose aspirin may be considered, though bleeding risk increases. Direct oral anticoagulants (DOACs—rivaroxaban, apixaban) are NOT recommended for high-risk APS (triple-positive, arterial thrombosis), as trials demonstrated increased recurrent thrombosis compared to warfarin. For patients with APS AND pregnancy morbidity: LOW-DOSE ASPIRIN (75-100mg daily) plus PROPHYLACTIC LOW MOLECULAR WEIGHT HEPARIN (enoxaparin 40mg daily) throughout pregnancy and 6 weeks postpartum. This regimen increases live birth rates from <20% to 70-80%. For patients with incidental aPL (no clinical events): low-dose aspirin is often prescribed for primary prophylaxis in high-risk profiles (triple-positive, SLE), though benefit is uncertain. For Catastrophic APS: triple therapy—anticoagulation (heparin), high-dose corticosteroids, plasma exchange OR IVIG. Cyclophosphamide, rituximab, eculizumab are used in refractory cases. Prognosis: With appropriate anticoagulation, recurrent thrombosis risk is reduced from 50-70% to 1-5% annually. However, thrombosis recurs in 20-30% of patients on warfarin, often due to subtherapeutic INR. Pregnancy outcomes are dramatically improved with combined aspirin-heparin therapy. Catastrophic APS remains highly lethal. For Zambian clinicians, specific challenges include limited availability of aPL testing and reliance on clinical diagnosis in high-probability scenarios; the high prevalence of SLE and HIV (which may cause transient aPL) in the Zambian population; limited access to LMWH and INR monitoring; and the absence of DOACs in public formularies. Despite these challenges, APS is a major preventable cause of stroke in young adults and recurrent pregnancy loss. High clinical suspicion in young patients with unexplained thrombosis or pregnancy morbidity, confirmation of persistent aPL where possible, and life-long warfarin therapy (accessible, inexpensive, monitorable with INR) are feasible and life-saving interventions. Patient education regarding medication adherence, INR target range, pregnancy planning, and warning signs of thrombosis is essential. This topic empowers Zambian healthcare workers to identify, investigate, and manage this devastating but highly treatable thrombophilic disorder.
-
Coming soon
Topic 159Coming soon
Sarcoidosis
Sarcoidosis is a multisystem granulomatous disorder of unknown etiology characterized by non-caseating epithelioid granulomas, most commonly affecting the lungs and intrathoracic lymph nodes, but capable of involving virtually any organ system. This comprehensive topic provides Zambian tertiary nursing and medical students with essential knowledge for recognizing this great imitator, which may present to virtually any clinical service, and for distinguishing it from tuberculosis—a critical diagnostic challenge in high-burden settings. The pathophysiology of sarcoidosis involves an exaggerated cellular immune response to an unknown antigen in genetically susceptible individuals. The inciting antigen is hypothesized to be microbial (mycobacterial, propionibacterial), environmental (beryllium, aluminum, zirconium), or autoimmune. In affected organs, antigen presentation via HLA class II molecules (particularly HLA-DRB1*03, *11, *12, *14, *15) to CD4+ T lymphocytes triggers oligoclonal T cell expansion and Th1/Th17 polarization. Activated T cells secrete IL-2, IFN-γ, and TNF-α, recruiting and activating macrophages. Macrophages differentiate into epithelioid histiocytes and fuse to form multinucleated giant cells (Langhans-type), aggregating into well-formed, compact, non-caseating granulomas surrounded by lymphocytes (CD4+ T cells, fewer CD8+ T cells) and fibroblasts. Unlike tuberculosis, the center of sarcoid granulomas undergoes fibrinoid necrosis or hyalinization, not caseous necrosis. Over time, granulomas may resolve spontaneously (two-thirds) or progress to irreversible fibrosis, causing end-organ damage. The clinical presentation of sarcoidosis is extraordinarily diverse, ranging from asymptomatic incidental radiographic findings to life-threatening organ failure. PULMONARY (90%): The lung is the most commonly involved organ. Intrathoracic lymphadenopathy (bilateral hilar, right paratracheal) is the classic radiographic finding. Pulmonary parenchymal disease manifests as dyspnea, dry cough, chest discomfort. Radiographic stages (Scadding): Stage 0 (normal), Stage I (bilateral hilar lymphadenopathy alone), Stage II (lymphadenopathy + parenchymal infiltrates), Stage III (parenchymal infiltrates alone), Stage IV (fibrosis, honeycombing). Pulmonary function tests reveal restrictive pattern with reduced DLCO. LYMPHATIC (30%): Peripheral lymphadenopathy (cervical, axillary, inguinal—discrete, nontender, mobile), splenomegaly. CUTANEOUS (25%): Erythema nodosum (acute, painful, pretibial nodules—associated with Lofgren's syndrome), lupus pernio (chronic, violaceous, indurated plaques on nose, cheeks, ears—disfiguring, associated with chronic fibrotic disease), maculopapular lesions, scar infiltration. OCULAR (25%): Anterior uveitis (acute or chronic), intermediate/posterior uveitis, conjunctival nodules, lacrimal gland enlargement, optic neuritis. Uveitis is a common extrapulmonary presentation and cause of morbidity. CARDIAC (5% clinically, 25% autopsy): Granulomatous infiltration of myocardium—conduction abnormalities (heart block, bundle branch block, ventricular tachycardia), cardiomyopathy, sudden cardiac death. Cardiac sarcoidosis is a major cause of mortality. NEUROLOGIC (5-10%): Cranial neuropathies (facial nerve palsy—bilateral, peripheral VII), aseptic meningitis, hypothalamic-pituitary dysfunction (diabetes insipidus), mass lesions, peripheral neuropathy, small fiber neuropathy. Neurosarcoidosis is highly morbid. HEPATIC (20-30%): Granulomatous hepatitis, cholestatic liver enzyme elevation, rarely cirrhosis/portal hypertension. RENAL: Hypercalciuria (due to macrophage 1α-hydroxylase activity, extrarenal calcitriol synthesis), nephrolithiasis, rarely granulomatous interstitial nephritis. ENDOCRINE: Hypercalcemia (5-10%), diabetes insipidus (hypothalamic), anterior pituitary dysfunction. MUSCULOSKELETAL: Arthralgia, acute arthritis (Lofgren's syndrome), chronic arthritis, osseous lesions (cystic, lytic). CONSTITUTIONAL: Fatigue, fever, night sweats, weight loss. LOFGREN'S SYNDROME: acute presentation of erythema nodosum, bilateral hilar lymphadenopathy, and polyarthritis (ankles). Highly predictive of self-limited disease, excellent prognosis. HEERFORDT'S SYNDROME: uveitis, parotid enlargement, facial nerve palsy, fever—chronic, relapsing course. Diagnosis of sarcoidosis requires THREE elements: compatible clinical and radiographic presentation, histopathologic demonstration of non-caseating granulomas, and EXCLUSION of other granulomatous diseases (particularly tuberculosis, fungal infection, mycobacterial infection, berylliosis, lymphoma). TISSUE BIOPSY is essential for definitive diagnosis unless classic Lofgren's syndrome. Accessible biopsy sites: transbronchial lung biopsy (via bronchoscopy, diagnostic yield 40-90%, depending on stage), endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) of mediastinal/hilar lymph nodes (diagnostic yield >80%), peripheral lymph node biopsy, skin biopsy, conjunctival/lacrimal gland biopsy, liver biopsy. Histopathology: well-formed, compact, non-caseating epithelioid granulomas with multinucleated giant cells (Langhans-type, foreign body-type), concentric lamellar calcifications (Schaumann bodies), stellate inclusions (asteroid bodies). Special stains (AFB, GMS) and cultures MUST be negative to exclude tuberculosis and fungi. Laboratory findings are supportive but non-diagnostic. Serum angiotensin-converting enzyme (ACE) is elevated in 60-70% of patients (produced by epithelioid macrophages), but lacks sensitivity and specificity. Hypercalciuria (40%) > hypercalcemia (5%). Hypergammaglobulinemia, elevated ESR/CRP, lymphopenia. Tuberculin skin test (PPD) or interferon-gamma release assay (IGRA) is typically ANERGIC (negative) due to peripheral anergy, but a positive test does NOT exclude sarcoidosis (coexistent LTBI). Imaging: Chest radiography (staging), HRCT (nodular peribronchovascular thickening, septal lines, ground glass, fibrosis), PET-CT (increased FDG uptake in active granulomatous inflammation, assesses disease extent, guides biopsy), Gallium-67 scanning (panda sign—lacrimal/parotid uptake, lambda sign—bilateral hilar/right paratracheal uptake). Pulmonary function tests: spirometry, lung volumes, DLCO. Ophthalmologic examination: slit-lamp examination for uveitis. Electrocardiogram, echocardiogram, cardiac MRI/PET for suspected cardiac sarcoidosis. Management of sarcoidosis is guided by two principles: asymptomatic, non-progressive disease does NOT require treatment, and treatment is indicated for organ-threatening or life-threatening disease, significant symptoms, or progressive dysfunction. The decision to treat is based on organ involvement, severity, and likelihood of spontaneous remission. FIRST-LINE THERAPY: CORTICOSTEROIDS. Oral prednisone (20-40 mg daily) is the mainstay for moderate-severe disease. Taper to lowest effective dose over 6-12 months. Topical corticosteroids: cutaneous, ocular, inhaled (airway disease). SECOND-LINE/STEROID-SPARING AGENTS: Methotrexate (10-25 mg weekly)—most commonly used, effective for cutaneous, pulmonary, ocular disease. Azathioprine, leflunomide, mycophenolate mofetil are alternatives. THIRD-LINE/BIOLOGIC AGENTS: TNF inhibitors—infliximab, adalimumab—effective for refractory pulmonary, cutaneous, neurologic, cardiac sarcoidosis. Etanercept is INEFFECTIVE. Antimalarials (hydroxychloroquine, chloroquine): effective for cutaneous sarcoidosis, hypercalcemia. ORGAN-SPECIFIC: Cardiac—corticosteroids, consider implantable cardioverter-defibrillator for life-threatening arrhythmias. Neurologic—corticosteroids, TNF inhibitors. Ocular—topical, periocular, systemic corticosteroids, methotrexate, TNF inhibitors. Pulmonary fibrosis—supportive care, oxygen, pulmonary rehabilitation, lung transplantation (end-stage). Hypercalcemia/hypercalciuria: corticosteroids, hydroxychloroquine, low-calcium diet, avoid vitamin D/sunlight. Prognosis: Overall, two-thirds of patients experience spontaneous remission within 10 years. One-third have chronic progressive disease. Mortality (1-5%) is due to respiratory failure (pulmonary fibrosis), cardiac sarcoidosis, and neurologic involvement. Poor prognostic factors: advanced age at onset, Black race, chronic progressive disease, extrapulmonary involvement (cardiac, neurologic, lupus pernio), radiographic stage III/IV, pulmonary hypertension. For Zambian clinicians, sarcoidosis presents a profound diagnostic challenge—it must be distinguished from TUBERCULOSIS, which is endemic, presents similarly with pulmonary infiltrates, lymphadenopathy, and granulomatous inflammation, but requires dramatically different treatment. Misdiagnosis of sarcoidosis as TB leads to unnecessary anti-tuberculous therapy (with attendant toxicity) and failure to initiate corticosteroids; misdiagnosis of TB as sarcoidosis leads to disseminated, potentially fatal tuberculosis. Key distinctions: TB granulomas typically caseating (though non-caseating in HIV), AFB smear/culture/PCR positive, PPD/IGRA positive, clinical and radiographic progression without anti-TB therapy. In Zambia, many patients diagnosed with 'sarcoidosis' likely have culture-negative TB or TB-IRIS. Thus, a PRESUMPTIVE DIAGNOSIS OF SARCOIDOSIS IN ZAMBIA REQUIRES EXCLUSION OF TUBERCULOSIS WITH MAXIMUM EFFORT—including negative AFB smears (sputum, tissue), negative mycobacterial culture, negative TB-PCR (Xpert MTB/RIF), AND failure to respond to anti-TB therapy (if empirically treated). Even with negative studies, clinical vigilance for TB is mandatory, and empiric anti-TB therapy should be strongly considered in high-risk patients. For patients with confirmed sarcoidosis, treatment follows international guidelines, adapted to local medication availability. Prednisone is accessible and inexpensive. Methotrexate is accessible. TNF inhibitors are largely unavailable. Hydroxychloroquine is accessible for cutaneous disease. Monitoring for corticosteroid toxicity (diabetes, hypertension, osteoporosis, cataracts, infection—including TB reactivation) is essential. Patient education addresses the unpredictable natural history (may resolve, may progress), importance of regular monitoring, medication adherence, and recognition of relapse symptoms. This topic equips Zambian healthcare workers with the sophisticated diagnostic and therapeutic knowledge required to navigate the challenging intersection of sarcoidosis and tuberculosis in high-burden settings.
-
Coming soon
Topic 160Coming soon
Fibromyalgia
Fibromyalgia is a complex, chronic disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbance, cognitive dysfunction, and multiple somatic symptoms, representing a disorder of central pain processing and sensitization rather than peripheral tissue inflammation or damage. This comprehensive topic provides Zambian tertiary nursing and medical students with essential knowledge for recognizing this common but frequently misunderstood condition, distinguishing it from inflammatory rheumatic diseases, and implementing evidence-based, multimodal management strategies that improve function and quality of life despite the absence of curative therapy. The pathophysiology of fibromyalgia has evolved dramatically from a peripheral musculoskeletal disorder to a paradigmatic CENTRAL SENSITIZATION SYNDROME. Functional neuroimaging (fMRI, PET) demonstrates AUGMENTED PAIN PROCESSING: patients with fibromyalgia exhibit increased neuronal activation in pain-related cortical regions (insula, anterior cingulate cortex, primary/secondary somatosensory cortex) in response to both noxious and non-noxious stimuli at lower thresholds than healthy controls. Conversely, descending inhibitory pain pathways (periaqueductal gray, rostral ventromedial medulla) are DYSFUNCTIONAL, failing to dampen ascending nociceptive signals. NEUROCHEMICAL ABNORMALITIES include elevated excitatory neurotransmitters (glutamate, substance P) and decreased inhibitory neurotransmitters (serotonin, norepinephrine, GABA) in cerebrospinal fluid and relevant brain regions. AUTONOMIC NERVOUS SYSTEM DYSFUNCTION (sympathetic hyperactivity, reduced heart rate variability), NEUROENDOCRINE DISTURBANCES (hypothalamic-pituitary-adrenal axis hyporesponsiveness), and sleep disorders (loss of deep slow-wave sleep) contribute to symptom perpetuation. Peripheral factors—including small fiber neuropathy (demonstrated by skin biopsy in 40-50%), myofascial trigger points, and comorbid peripheral pain generators (osteoarthritis, tendinopathy)—may serve as afferent input that initiates and maintains central sensitization. Genetic susceptibility involves polymorphisms in serotonin, dopamine, and catecholamine pathway genes. Importantly, fibromyalgia is NOT an autoimmune, inflammatory, or degenerative musculoskeletal disease; there is NO tissue inflammation, NO joint destruction, NO muscle pathology. The clinical presentation of fibromyalgia is dominated by CHRONIC, WIDESPREAD PAIN (present >3 months, bilateral, above and below waist, axial skeleton), typically described as deep aching, burning, throbbing, or stabbing, with fluctuating intensity. The 1990 ACR classification criteria required manual tender point examination (≥11 of 18 specific points); this has been superseded by the 2010/2016 ACR diagnostic criteria, which emphasize the WIDESPREAD PAIN INDEX (WPI, number of painful body regions, 0-19) and SYMPTOM SEVERITY SCALE (SSS, 0-12), incorporating fatigue, unrefreshing sleep, cognitive symptoms, and somatic symptom burden. FATIGUE (75-90%) is profound, often described as 'brain fog' or exhaustion disproportionate to activity, present upon awakening despite adequate sleep duration. SLEEP DISTURBANCE (70-80%) includes difficulty initiating/maintaining sleep, non-restorative sleep, and restless legs syndrome. COGNITIVE DYSFUNCTION ('fibrofog', 50-70%) includes impaired short-term memory, word-finding difficulty, concentration deficits, and mental slowness. MOOD DISORDERS (30-60%): major depression, anxiety disorders—often reactive but may be comorbid. SOMATIC SYMPTOMS: headache (tension-type, migraine), irritable bowel syndrome (40-70%), interstitial cystitis/bladder pain syndrome, temporomandibular joint dysfunction, paresthesia without objective neuropathy, dizziness, palpitations, dysmenorrhea. Physical examination is notable for the ABSENCE of synovitis, muscle weakness, neuropathy, or rash. Tenderness to palpation may be widespread but is not limited to specific tender points. Diagnosis is CLINICAL, based on characteristic symptom complex and EXCLUSION of other disorders that could explain the symptoms. NO diagnostic laboratory test or imaging study confirms fibromyalgia. However, limited laboratory testing is essential to exclude mimicking conditions: complete blood count, ESR, CRP, thyroid function tests, vitamin D, creatine kinase, and screening for autoimmune disease if clinically indicated (ANA, RF). Importantly, inflammatory markers (ESR, CRP) are NORMAL in fibromyalgia; ELEVATED markers suggest inflammatory arthritis, connective tissue disease, infection, or malignancy and should prompt further investigation. The differential diagnosis includes: inflammatory arthritis (RA, SpA, SLE—distinguished by synovitis, inflammatory arthritis on exam, elevated acute phase reactants, autoantibodies), polymyalgia rheumatica (age >50, dramatic steroid response, elevated ESR/CRP), hypothyroidism (TSH), hyperparathyroidism (calcium, PTH), vitamin D deficiency, myopathy (CK elevated), and statin-induced myalgia. Fibromyalgia is NOT a diagnosis of exclusion; it is a POSITIVE DIAGNOSIS based on characteristic symptom criteria in the absence of alternative explanation. Importantly, fibromyalgia frequently CO-EXISTS with inflammatory rheumatic diseases (RA, SLE, SpA, OA)—20-30% of patients with these conditions meet fibromyalgia criteria, and comorbid fibromyalgia amplifies pain reporting, disability, and disease activity scores, confounding assessment of underlying inflammatory disease activity. Management of fibromyalgia requires a MULTIMODAL, INDIVIDUALIZED, PATIENT-CENTERED approach, emphasizing SELF-MANAGEMENT and functional improvement rather than complete pain elimination. Treatment is stratified into NON-PHARMACOLOGICAL (first-line, foundational) and PHARMACOLOGICAL (adjunctive) interventions. NON-PHARMACOLOGICAL: PATIENT EDUCATION is paramount—validating the reality of symptoms, explaining the pathophysiology of central sensitization (the 'volume control' analogy: pain signal volume turned up too high), establishing realistic goals (improved function, not zero pain), and shifting focus from passive symptom relief to active self-management. EXERCISE is the MOST EFFECTIVE evidence-based intervention. A graded, incremental approach: start with low-intensity, low-impact activities (walking, swimming, water aerobics, stationary cycling), 5-10 minutes daily, gradually increasing duration and frequency. Goal: 30 minutes moderate aerobic activity 3-4x weekly. Strength training and flexibility exercises (yoga, tai chi) are beneficial. Adherence is challenging but critical; initial exacerbation of pain is common and should be anticipated, not misinterpreted as harm. COGNITIVE BEHAVIORAL THERAPY reduces pain, fatigue, and disability by addressing maladaptive thoughts, pain catastrophizing, fear-avoidance behaviors, and promoting adaptive coping strategies. SLEEP HYGIENE: consistent sleep-wake schedule, stimulus control, avoidance of caffeine/alcohol before bed, relaxation techniques. Other modalities: acupuncture, mindfulness meditation, biofeedback—variable evidence. PHARMACOLOGICAL: Medications are ADJUNCTIVE, not curative, and should be initiated ONE AT A TIME, at LOW DOSE, with SLOW TITRATION, monitoring for efficacy and adverse effects. FIRST-LINE: GABAPENTINOIDS—pregabalin (75-150mg bid, titrated to 300-450mg/day) and gabapentin (1200-2400mg/day). Efficacy modest (30% reduction in pain vs 20% placebo). Adverse effects: dizziness, somnolence, weight gain, peripheral edema. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS—duloxetine (30-60mg daily, max 120mg) and milnacipran (50-100mg bid). Efficacy: pain, fatigue, functional improvement. Adverse effects: nausea, dry mouth, constipation, insomnia, hypertension. SECOND-LINE: TRICYCLIC ANTIDEPRESSANTS—amitriptyline (10-50mg at bedtime) improves sleep, pain, fatigue. Cyclobenzaprine (5-10mg at bedtime)—muscle relaxant structurally related to tricyclics. Efficacy modest, limited by anticholinergic side effects. Medications with LIMITED or NO EFFICACY: NSAIDs, corticosteroids, opioids (AVOID—no efficacy, risk of opioid-induced hyperalgesia, addiction, overdose), benzodiazepines, strong anticonvulsants (carbamazepine, phenytoin). CANNABINOIDS: insufficient evidence. Prognosis: Fibromyalgia is a CHRONIC condition; complete remission is uncommon. However, with appropriate education, exercise, and multimodal therapy, the majority of patients achieve significant functional improvement and acceptable symptom control. Poor prognostic factors: high baseline symptom severity, comorbid mood disorders, disability/compensation claims, poor social support, passive coping style. The therapeutic relationship is critical—validation, empathy, consistency, and realistic hope are powerful interventions. For Zambian clinicians, fibromyalgia presents specific challenges and opportunities. Awareness among healthcare providers is variable; patients may be dismissed, stigmatized, or subjected to unnecessary investigations and treatments. Competing burdens of infectious diseases (HIV, TB, malaria) and nutritional deficiencies may overshadow non-communicable pain disorders. Access to non-pharmacological therapies (specialized physiotherapy, CBT, graded exercise programs) is extremely limited. Pharmacological options: amitriptyline is inexpensive, widely available, and effective for sleep and pain. Gabapentin is increasingly available, though cost may be prohibitive. Duloxetine is expensive. Pregabalin, milnacipran are largely unavailable. NSAIDs and opioids are commonly prescribed but INEFFECTIVE and potentially harmful. Despite these constraints, substantial improvement is achievable. The cornerstone is PATIENT EDUCATION: a single, empathetic, explanatory consultation may be transformative. Validation—'Your pain is real, it is not in your head, there is a biological explanation, and we can work together to improve your function'—is therapeutic. Simple, accessible interventions: graded walking programs, community-based exercise groups, sleep hygiene counseling, and low-dose amitriptyline are feasible and effective. Referral to physiotherapy, clinical psychology, and psychiatry where available. Avoidance of opioids and unnecessary investigations is essential. For Zambian nurses and clinicians, comprehensive fibromyalgia knowledge enables confident diagnosis of this common, real, and treatable condition; distinction from inflammatory rheumatic diseases; implementation of evidence-based, context-appropriate multimodal management; provision of validating, empowering patient education; and avoidance of ineffective and potentially harmful interventions. This knowledge transforms the clinical encounter from one of frustration and futility to one of understanding, partnership, and meaningful functional improvement.
-
Coming soon
Topic 161Coming soon
Hepatitis B and C-Associated Arthritis
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are associated with diverse extrahepatic manifestations, including inflammatory arthritis that may mimic rheumatoid arthritis and other systemic rheumatic diseases. This comprehensive topic provides Zambian tertiary nursing and medical students with essential knowledge for recognizing viral arthritis in a high-prevalence setting, distinguishing it from autoimmune inflammatory arthritis, and implementing appropriate diagnostic and therapeutic strategies that address both the articular and hepatic manifestations without causing viral reactivation or exacerbation of liver disease. The importance of this topic for Zambian clinicians cannot be overstated: Zambia has a high burden of chronic hepatitis B (HBsAg prevalence 5-10%) and hepatitis C (1-3%), with many patients undiagnosed until complications develop. Arthritis may be the presenting manifestation of viral hepatitis, and misdiagnosis as seronegative rheumatoid arthritis or undifferentiated inflammatory arthritis may lead to inappropriate immunosuppressive therapy, potentially causing life-threatening viral reactivation (HBV) or accelerated fibrosis (HCV). HEPATITIS B-ASSOCIATED ARTHRITIS occurs in two distinct clinical contexts: acute HBV infection (prodromal serum sickness-like syndrome) and chronic HBV infection with immune complex-mediated arthropathy. During the PRODROMAL PHASE of ACUTE HEPATITIS B (1-4 weeks before jaundice), 10-25% of patients develop an acute, symmetric POLYARTHRITIS affecting small joints of hands (PIP, MCP), wrists, knees, ankles—clinically indistinguishable from acute rheumatoid arthritis. This is mediated by circulating immune complexes containing HBsAg and complement, depositing in synovium. Characteristic features: sudden onset, morning stiffness, tenosynovitis (25%), and often accompanied by urticarial or maculopapular rash (50%). The arthritis is NON-EROSIVE and SELF-LIMITED, resolving spontaneously within 1-3 weeks with the onset of jaundice and clearance of HBsAg (in self-limited acute infection). Importantly, rheumatoid factor may be transiently positive (20-30%), and serum complement (C3, C4, CH50) is typically LOW during this phase due to immune complex consumption. In CHRONIC HEPATITIS B infection, a minority of patients (2-5%) develop chronic or relapsing oligoarthritis/polyarthritis, also mediated by immune complex deposition. This arthritis is typically MILD, NON-EROSIVE, and does NOT cause joint deformity. It may be associated with other extrahepatic manifestations of chronic HBV: polyarteritis nodosa (PAN)—systemic necrotizing vasculitis affecting medium arteries, presenting with mononeuritis multiplex, abdominal pain, hypertension, renal involvement, skin ulcers; and membranous nephropathy, membranoproliferative glomerulonephritis. Diagnosis of HBV-associated arthritis requires: 1) inflammatory arthritis (acute or chronic), 2) evidence of HBV infection (HBsAg positive for chronic; IgM anti-HBc positive for acute), 3) exclusion of other causes of arthritis, and 4) in chronic cases, lack of erosions/deformities and absence of RA-specific autoantibodies (ACPA is NEGATIVE; RF may be positive). Hepatitis B serology interpretation is critical: ACUTE HBV = HBsAg+, IgM anti-HBc+, anti-HBs-; CHRONIC HBV = HBsAg+ >6 months, IgG anti-HBc+, IgM anti-HBc- (or low-titre), anti-HBs-; RESOLVED HBV = HBsAg-, anti-HBc+, anti-HBs+; VACCINATED = anti-HBs+, anti-HBc-. HBV DNA level indicates viral replication. HEPATITIS C-ASSOCIATED ARTHRITIS is more common than HBV-associated arthritis, occurring in 10-30% of chronic HCV patients. Two distinct patterns are recognized: a SYMMETRIC POLYARTHRITIS involving small joints (PIP, MCP, wrists) that closely mimics RHEUMATOID ARTHRITIS (HCV-RA mimic), and an ASYMMETRIC OLIGOARTHRITIS involving large and medium joints (knees, ankles) that mimics SPONDYLOARTHRITIS. Importantly, HCV arthritis is typically NON-EROSIVE (90-95%) and RHEUMATOID FACTOR is POSITIVE in 50-80% of chronic HCV patients (due to chronic immune stimulation, mixed cryoglobulinemia), while ANTI-CCP (ACPA) is NEGATIVE (>95%). This serologic profile—RF positive, ACPA negative—is a key diagnostic clue distinguishing HCV-arthritis from true RA (both RF and ACPA positive in 70-80%). The arthritis may be associated with other HCV extrahepatic manifestations: MIXED CRYOGLOBULINEMIA (30-50%)—type II (monoclonal IgM rheumatoid factor + polyclonal IgG) or type III (polyclonal IgM rheumatoid factor + polyclonal IgG)—presenting with palpable purpura (lower extremities), peripheral neuropathy, glomerulonephritis; SICCA SYNDROME (10-25%)—dry eyes, dry mouth, often with anti-Ro/La antibodies; and THYROID DISEASE. Diagnosis of HCV-associated arthritis requires: 1) inflammatory arthritis (acute or chronic), 2) evidence of chronic HCV infection (anti-HCV+, HCV RNA+), 3) exclusion of other causes, 4) absence of erosions and ACPA negativity. Liver disease staging (fibrosis/cirrhosis) by transient elastography (FibroScan) or non-invasive serum markers (APRI, FIB-4) is essential for prognosis and treatment decisions. The differential diagnosis of viral arthritis includes: RHEUMATOID ARTHRITIS (distinguished by ACPA positivity, erosive disease, persistent synovitis despite antiviral therapy), SYSTEMIC LUPUS ERYTHEMATOSUS (ANA, anti-dsDNA, other autoantibodies, characteristic multi-organ involvement), PARVOVIRUS B19 ARTHRITIS (acute, self-limited, often with lacy reticular rash, IgM anti-parvovirus), HIV-ASSOCIATED ARTHRITIS (HIV-positive, often oligoarticular, lower extremity predominant, may be part of IRIS), and OTHER VIRAL ARTHRITIDES (rubella, alphaviruses—chikungunya, o'nyong-nyong, which causes epidemic polyarthritis in Africa). Management of HBV- and HCV-associated arthritis is guided by three principles: 1) treat the UNDERLYING VIRAL INFECTION—antiviral therapy is the definitive treatment for viral arthritis, 2) provide SYMPTOMATIC arthritis control with agents that do NOT exacerbate liver disease or cause viral reactivation, and 3) AVOID IMMUNOSUPPRESSION in untreated viral hepatitis. For HBV-ASSOCIATED ARTHRITIS: In acute HBV, arthritis is self-limited; treat symptomatically with acetaminophen (paracetamol), NSAIDs (avoid in decompensated liver disease). Antiviral therapy is generally NOT indicated for acute HBV ( >95% spontaneous resolution in immunocompetent adults). In chronic HBV with arthritis, initiate ORAL ANTIVIRAL THERAPY (tenofovir disoproxil fumarate, tenofovir alafenamide, entecavir). These agents are highly effective, well-tolerated, suppress HBV DNA, and lead to improvement/resolution of arthritis in most patients over weeks-months. For symptomatic arthritis control: acetaminophen, NSAIDs (caution in cirrhosis—risk of decompensation, renal impairment), hydroxychloroquine (safe, effective), low-dose corticosteroids (short-term, monitor HBV DNA). IMPORTANT: If immunosuppression (corticosteroids, methotrexate, TNF inhibitors) is absolutely necessary for severe refractory arthritis, ANTIVIRAL PROPHYLAXIS MUST BE INITIATED CONCURRENTLY to prevent HBV reactivation (which can be fulminant and fatal). For HCV-ASSOCIATED ARTHRITIS: Definitive treatment is DIRECT-ACTING ANTIVIRAL (DAA) THERAPY. Modern DAA regimens (sofosbuvir, daclatasvir, ledipasvir, velpatasvir) achieve SUSTAINED VIROLOGIC RESPONSE (SVR, viral cure) in >95% of patients, are well-tolerated, short duration (8-12 weeks), and lead to improvement or resolution of arthritis in 50-70% of patients. Symptomatic arthritis control: acetaminophen, NSAIDs (caution in cirrhosis), hydroxychloroquine (safe, effective), low-dose corticosteroids (short-term). Methotrexate, leflunomide, sulfasalazine, TNF inhibitors have been used with caution in HCV (pre-DAA era), but are now rarely needed if antiviral therapy is accessible. Importantly, there is NO contraindication to using these agents in HCV if viral therapy is unavailable or arthritis persists post-SVR, provided liver function is monitored. Rituximab is used for severe, refractory mixed cryoglobulinemia vasculitis. Prognosis: With effective antiviral therapy, viral arthritis has an excellent prognosis—complete or partial resolution in most patients. Persistent arthritis post-SVR may represent: 1) irreversible joint damage (rare, non-erosive), 2) comorbid osteoarthritis, or 3) development of true autoimmune RA (rare, coincidental). For Zambian clinicians, specific challenges include the high prevalence of undiagnosed HBV and HCV in patients presenting with inflammatory arthritis, limited access to HBV DNA and HCV RNA testing for viral confirmation and treatment monitoring, increasing but not universal access to oral antivirals (tenofovir for HBV; DAAs for HCV), and the need to navigate this complex differential diagnosis with limited rheumatology and hepatology specialist support. Despite these challenges, a structured diagnostic approach is feasible and essential. EVERY PATIENT presenting with new-onset inflammatory arthritis in Zambia should undergo hepatitis B (HBsAg, anti-HBc) and hepatitis C (anti-HCV) serologic screening. HBsAg-positive patients require HBV DNA testing (viral load), LFTs, and consideration of tenofovir therapy. Anti-HCV-positive patients require HCV RNA testing (confirm active infection), genotype (if available), LFTs, fibrosis assessment, and DAA therapy. Arthritis management is primarily antiviral therapy; symptomatic control with acetaminophen, NSAIDs, hydroxychloroquine is safe and accessible. Immunosuppression without antiviral coverage in untreated HBV is DANGEROUS and must be avoided. This topic equips Zambian healthcare workers with the knowledge and clinical algorithms to recognize viral arthritis, diagnose underlying hepatitis infection, initiate appropriate antiviral therapy, provide safe symptomatic relief, and prevent catastrophic treatment errors in this common and eminently treatable condition.
-
Coming soon
Topic 162Coming soon
HIV-Associated Arthritis
HIV infection is associated with diverse rheumatic manifestations throughout disease course. For Zambian students, essential knowledge in high-prevalence setting. Pathophysiology: direct HIV infection of synovium? Immune dysregulation, CD8+ T cell infiltration, reactive arthritis mechanisms. Clinical: HIV-ASSOCIATED ARTHRITIS—acute/subacute, asymmetric oligoarthritis, lower extremity (knees, ankles), non-erosive. May resemble reactive arthritis (ReA) without classic triad. HIV-ASSOCIATED ReA: more severe, refractory, associated with HLA-B27. PSORIASIS/PSORIATIC ARTHRITIS: increased incidence, severity with immunosuppression. SICCA SYNDROME: diffuse infiltrative lymphocytosis syndrome (DILS)—CD8+ infiltration of salivary glands, lungs, nerves, mimics Sjögren's but anti-Ro/La negative, HIV+; responds to ART. SEPTIC ARTHRITIS: increased risk (IVDU, immunosuppression), atypical organisms. IRIS: ART initiation may unmask/reactivate rheumatic disease (ReA, PsA, sarcoidosis). Diagnosis: HIV serology. Synovial fluid: inflammatory, exclude septic. DILS: CD8+ lymphocytes in tissue, HIV+. Management: ANTIRETROVIRAL THERAPY (ART) is cornerstone—improves/prevents many manifestations. NSAIDs, intra-articular corticosteroids. Sulfasalazine, methotrexate for refractory ReA/PsA (caution: monitor CD4, viral load). TNF inhibitors: case reports, caution in advanced immunosuppression. Prognosis: ART dramatically improves outcomes. Zambian context: high HIV prevalence, ART widely available. Consider HIV in all arthritis patients. DILS mimics Sjögren's; ART effective.